Molecular basis and genetic testing strategies for diagnosing 21-hydroxylase deficiency, including CAH-X syndrome
Annals of Pediatric Endocrinology & Metabolism · 30.06.2023 · 28 (2) · 77-86
DOI: 10.6065/apem.2346108.054 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Pediatric Endocrinology & Metabolism, erschienen am 30.06.2023. Verfasst von Ja Hye Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Science and ICT.
Abstract (Originalsprache)
Congenital adrenal hyperplasia (CAH) is a group of autosomally recessive disorders that result from impaired synthesis of glucocorticoid and mineralocorticoid. Most cases (~95%) are caused by mutations in the CYP21A2 gene, which encodes steroid 21-hydroxylase. CAH patients manifest a wide phenotypic spectrum according to their degree of residual enzyme activity. CYP21A2 and its pseudogene (CYP21A1P) are located 30 kb apart in the 6q21.3 region and share approximately 98% of their sequences in the coding region. Both genes are aligned in tandem with the C4, SKT19, and TNX genes, forming 2 segments of the RCCX modules that are arranged as STK19-C4A-CYP21A1P-TNXA-STK19B-C4B-CYP21A2-TNXB. The high sequence homology between the active gene and pseudogene leads to frequent microconversions and large rearrangements through intergenic recombination. The TNXB gene encodes an extracellular matrix glycoprotein, tenascin-X (TNX), and defects in TNXB cause Ehlers-Danlos syndrome. Deletions affecting both CYP21A2 and TNXB result in a contiguous gene deletion syndrome known as CAH-X syndrome. Because of the high homology between CYP21A2 and CYP21A1P, genetic testing for CAH should include an evaluation of copy number variations, as well as Sanger sequencing. Although it poses challenges for genetic testing, a large number of mutations and their associated phenotypes have been identified, which has helped to establish genotype-phenotype correlations. The genotype is helpful for guiding early treatment, predicting the clinical phenotype and prognosis, and providing genetic counseling. In particular, it can help ensure proper management of the potential complications of CAH-X syndrome, such as musculoskeletal and cardiac defects. This review focuses on the molecular pathophysiology and genetic diagnosis of 21-hydroxylase deficiency and highlights genetic testing strategies for CAH-X syndrome.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Medical Genetics Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Department of Pediatrics, Bundang CHA Medical Center, CHA University, Seongnam, Korea.
Förderung
- National Research Foundation of Korea
- Ministry of Science and ICT
Zitieren
APA
Kim, J. H., Kim, G. H., Yoo, H. W., & Choi, J. H. (2023). Molecular basis and genetic testing strategies for diagnosing 21-hydroxylase deficiency, including CAH-X syndrome. Annals of Pediatric Endocrinology & Metabolism, 28(2), 77-86. https://doi.org/10.6065/apem.2346108.054
Vancouver
Kim JH, Kim GH, Yoo HW, Choi JH. Molecular basis and genetic testing strategies for diagnosing 21-hydroxylase deficiency, including CAH-X syndrome. Annals of Pediatric Endocrinology & Metabolism. 2023;28(2):77-86. doi:10.6065/apem.2346108.054
BibTeX
@article{Kim2023,
author = {Kim, Ja Hye and Kim, Gu-Hwan and Yoo, Han-Wook and Choi, Jin-Ho},
title = {Molecular basis and genetic testing strategies for diagnosing 21-hydroxylase deficiency, including CAH-X syndrome},
journal = {Annals of Pediatric Endocrinology & Metabolism},
year = {2023},
volume = {28},
number = {2},
pages = {77--86},
doi = {10.6065/apem.2346108.054}
}
EUVIMED